Skip to main content
Premium Trial:

Request an Annual Quote

New Products Posted to GenomeWeb This Week: Intermountain Precision Genomics, Helomics/MDNA Life Sciences, and Cancer Genetics

Intermountain's ICG100 ONCO Focus Panel

Intermountain Precision Genomics, a cancer sequencing service provided by Intermountain Healthcare, is now offering the ICG100 ONCO Focus Panel. The next-generation sequencing panel analyzes five genes, KRAS, BRAF, NRAS, EGFR, and KIT, and is a leaner offering than the ICG100 Comprehensive Cancer panel which gauges 162 genes. Intermountain said that the five-gene panel requires as little as 20 nanograms of DNA, or between 5,000 and 8,000 cells, and has a two-day turnaround time, as opposed to the two weeks it takes to get back results from the comprehensive panel. The ICG100 ONCO Focus Panel evaluates genes that are frequently mutated in melanoma, lung, and colon cancers.

MDNA Prostate Mitomic Test

Helomics and MDNA Life Sciences have launched MDNA's Prostate Mitomic Test, a liquid biopsy test for early detection of high-grade prostate cancer independent of prostate-specific antigen and age. The test utilizes the company's Mitomic technology platform which exploits unique biologic characteristics of mitochondrial DNA and has a high negative predictive value which can be used to help clinicians determine which patients have a high-grade tumor that requires immediate intervention, the company said. The laboratory-developed test will be available exclusively through Helomics' clinical lab.

Cancer Genetics Liquid::Lung-cfDNA

Cancer Genetics has launched a new multi-gene liquid biopsy test for lung cancer, based on Thermo Fisher's Oncomine Lung Cell-Free DNA NGS assay. Run on the Ion S5 XL sequencing system, the test provides comprehensive coverage of 11 critical genes and over 150 key hotspots related to lung cancer and has a limit of detection of 0.05 percent.

For more new products and services, please visit the New Products page on our website.